Infliximab Biosimilars Not Linked to Worsened Infection Risk

An analysis of national Canadian data suggest patients receiving either originator or biosimilar infliximab are at a similar risk of the common adverse event.

Related Keywords

Canada ,Canadian ,Marinag Birck ,Linkedin Marinag Birck , ,Canadian National Prescription Drug Utilization Information System ,National Ambulatory Care Reporting System ,International Conference On Pharmacoepidemiology ,International Conference ,Therapeutic Risk Management ,Annual Meeting ,Research Institute ,Mcgill University Health Centre ,Hospital Discharge Abstract Database ,National Ambulatory Care Reporting ,Biosimilar ,Infliximab ,Biologic ,Infection ,Risk ,Safety ,Study ,Outcomes ,Remicade ,